Cookies

Like most websites The Medicine Maker uses cookies. In order to deliver a personalized, responsive service and to improve the site, we remember and store information about how you use it. Learn more.
Subscribe to Newsletter
Business & Regulation Standards & Regulation

Medicare Reveals Coverage Policy for Amyloid mAbs

Every journalist remembers their first interview – mine was with a researcher from the University of California about early Alzheimer’s work around amyloid beta plaques. Since then, I’ve held an interest in the field, but it’s not often I get to write about the topic. Why? Because breakthroughs in Alzheimer’s have been slim pickings, and there’s still no scientific consensus about what causes it – although amyloid beta plaques have remained a prominent theory.

In June 2021, the FDA approved Biogen’s Aduhelm (aducanumab) under its accelerated approval pathway. It was the first new therapy approved for Alzheimer’s since 2003. But can it really be classed as a “breakthrough?” After all, it’s difficult to ignore the controversy that has surrounded Aduhelm and its approval. If you’re out of the loop, feel free to catch up on what’s been going on with Aduhelm. In short, the main controversy stems from the fact that the drug was approved for its ability to reduce amyloid plaque in the brain. But will reduction of the plaques lead to better outcomes for Alzheimer’s patients? That’s the missing link, with some experts arguing there is no evidence.

In some cases, experts resigned from scientific advisory boards for groups that were lobbying CMS to cover the drug.

In light of the unknown, how should Medicare coverage work? The CMS has been debating this topic over the last few months. And, on April 7, the CMS revealed its final coverage policy. The policy was inspired by Aduhelm but will also apply to other mAbs directed against amyloid for treating Alzheimer’s (there are a few coming down pipelines). And the decision? The mAbs will be covered by Medicare – but only if the patient is part of a clinical trial.

Prior to the decision, the CMS held a consultation – receiving around 10,000 comments. And it was a bitter fight. Some comments heavily lobbied for access to the drug, while others were strongly against it. In some cases, experts resigned from scientific advisory boards for groups that were lobbying CMS to cover the drug.

Given how polarizing opinions were in the comment period, it’s no surprise that the final decision has also stirred up strong views. Perhaps the biggest point of contention is whether the CMS is going above its station. In a statement from the Biotechnology Innovation Organization, Michelle McMurray-Health, President and CEO, said, “With this decision, CMS is not just saying it has no confidence in Alzheimer’s drugs approved under the FDA’s Accelerated Approval pathway. It also is undermining confidence in FDA’s traditional drug approval process more broadly.”

Biogen has also commented that the type of coverage restrictions proposed by the CMS have never been applied to FDA-approved medicines in other disease areas.

As noted, other mAbs targeting amyloid are in development. And perhaps the argument will settle as more data emerges. In its statement, Biogen added, “When additional data from this new class of treatments become available, Biogen urges CMS to reconsider today’s decision for all FDA-approved amyloid-beta targeting therapies. For lecanemab, our partner Eisai has initiated FDA filing via the accelerated approval pathway and the readout of the Phase 3 confirmatory Clarity AD clinical trial is expected in the fall.”

Receive content, products, events as well as relevant industry updates from The Medicine Maker and its sponsors.
Stay up to date with our other newsletters and sponsors information, tailored specifically to the fields you are interested in

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.

About the Author
Stephanie Sutton

Making great scientific magazines isn’t just about delivering knowledge and high quality content; it’s also about packaging these in the right words to ensure that someone is truly inspired by a topic. My passion is ensuring that our authors’ expertise is presented as a seamless and enjoyable reading experience, whether in print, in digital or on social media. I’ve spent seven years writing and editing features for scientific and manufacturing publications, and in making this content engaging and accessible without sacrificing its scientific integrity. There is nothing better than a magazine with great content that feels great to read.

Register to The Medicine Maker

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Medicine Maker magazine

Register